Compare HYLN & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYLN | NVCT |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Construction/Ag Equipment/Trucks | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.1M | 274.5M |
| IPO Year | 2019 | 2021 |
| Metric | HYLN | NVCT |
|---|---|---|
| Price | $5.78 | $10.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 2.6M | 97.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,475,000.00 | N/A |
| Revenue This Year | $197.93 | N/A |
| Revenue Next Year | $301.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.28 | N/A |
| 52 Week Low | $1.14 | $5.55 |
| 52 Week High | $4.84 | $13.34 |
| Indicator | HYLN | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 86.80 | 52.68 |
| Support Level | $1.77 | $7.79 |
| Resistance Level | N/A | $13.34 |
| Average True Range (ATR) | 0.54 | 1.01 |
| MACD | 0.25 | -0.08 |
| Stochastic Oscillator | 91.75 | 32.40 |
Hyliion Holdings Corp designs and develops power generators for stationary and mobile applications and provides R&D service. It provides solutions that enable clean, flexible, and affordable electricity production. The company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies. Its products and services include: KARNO Power Modules which is a modular, fully enclosed, fuel-agnostic and fully integrated power generating solution.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.